Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.

ABSTRACT:

Objective

To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatment-resistant adolescents undergoing second-step treatment.

Method

The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatment-resistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating Scale-Revised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days.

Results

Multivariate analyses examining all five depression symptom dimensions simultaneously indicated

SUBMITTER: McMakin DL 

PROVIDER: S-EPMC3536476 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature